Abdulbasit Amin

ORCID, self-asserted

ORCID 0000-0001-5460-9581

Publications

Citations

h-index

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

Publications

8 works in the graph, newest first.

ADAM17 and its proteolytic targets in disease pathogenesis
2026FEBS JournalJournalOpen accessFirst author0 citations10.1111/febs.70516
Epidermal growth factor receptor modulation for neural repair: Implications for neurodegenerative disease therapy
2026Frontiers in Molecular NeuroscienceJournalOpen accessFirst author0 citations10.3389/fnmol.2026.1891964
Glucagon in glucose homeostasis and metabolic disease: from physiology to therapeutics
2025Journal of Basic and Clinical Physiology and PharmacologyJournalFirst author6 citations10.1515/jbcpp-2025-0005
Vitamin E-valproate co-therapy attenuated oxidative stress, neuroinflammation, related cognitive deficits and neuronal damage in Cypermethrin exacerbated seizure
2025BMC Pharmacology and ToxicologyJournalOpen access2 citations10.1186/s40360-025-01027-6
Optimization of Parkinson's disease therapy with plant extracts and nutrition’s evolving roles
2024IBRO Neuroscience ReportsJournalOpen access15 citations10.1016/j.ibneur.2024.05.011
The ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth
2023Life Science AllianceJournalOpen access18 citations10.26508/lsa.202201644
Semaphorin 4B is an ADAM17-cleaved adipokine that inhibits adipocyte differentiation and thermogenesis
2023Molecular MetabolismJournalOpen accessFirst author10 citations10.1016/j.molmet.2023.101731
Cholecalciferol (VD3) Attenuates L-DOPA-Induced Dyskinesia in Parkinsonian Mice Via Modulation of Microglia and Oxido-Inflammatory Mechanisms.
2022Nigerian Journal of Physiological SciencesJournalOpen access4 citations10.54548/njps.v37i2.3